Timeline
Last
$246.10
+2.30 (0.95%)
24HR+0.9%
1W-6.5%
1M-3.4%
1Y+24.0%
Valuation
- Market Cap
- $434.9B
- Enterprise Value
- $496.6B
- P/E (TTM)
- 69.52x
- Forward P/E
- 15.04x
- Price / Sales
- 6.75x
- EV / EBITDA
- 16.13x
Cash Flow
- Operating Cash Flow
- —
- Free Cash Flow
- —
- FCF Margin
- —
- Cash Conversion
- —
- Cash / Share
- $5.3
Margins & Growth
- Gross Margin
- 72.8%
- Operating Margin
- 39.6%
- EBITDA Margin
- 47.8%
- Net Margin
- 9.8%
- Revenue Growth
- 10.2%
- Earnings Growth
- 290.4%
Balance Sheet
- Total Cash
- $9.4B
- Total Debt
- $72.9B
- Net Cash
- -$63.5B
- Debt / Equity
- —
- Current Ratio
- —
- Quick Ratio
- —
Returns & Ownership
- Return on Assets
- —
- Return on Equity
- —
- Dividend Yield
- 2.8%
- Payout Ratio
- 189.9%
- Beta
- 0.28
- Institutional Ownership
- 76.8%
Latest EPS$3.65+0.0% surprise
Beat rate75%1 print streak
Avg surprise+0.0%vs consensus
Next printOct 29, 2026EPS $3.87
Quarterly EPS vs consensus
4 quarters Actual ConsensusLabels: beat $ · YoY %Revisions 18 up / 28 down
Earnings transcripts
Read management commentary and analyst Q&A.
No transcript dates are available yet for this ticker.
Forward estimates
Consensus expectations and estimate momentum.
PeriodEPSRevenueGrowth
0QSep 2026
$3.87$17.3B+108.2%+1QDec 2026
$3.96$18.2B+46.0%0YDec 2026
$14.12$67.6B+41.2%+1YDec 2027
$16.36$73.1B+15.9%Primary research
Recent company filings
Jump directly to earnings releases, quarterly reports, and material updates.
10-QPeriodic Financial Reports2026-08-038-KCorporate Changes & Voting Matters2026-07-318-KCorporate Changes & Voting Matters2026-07-068-KCorporate Changes & Voting Matters2026-06-228-KCorporate Changes & Voting Matters2026-05-1210-QPeriodic Financial Reports2026-05-088-KCorporate Changes & Voting Matters2026-04-298-KCorporate Changes & Voting Matters2026-04-038-KCorporate Changes & Voting Matters2026-03-0410-KPeriodic Financial Reports2026-02-208-KCorporate Changes & Voting Matters2026-02-048-KCorporate Changes & Voting Matters2026-01-07
ABBV stock research · AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly…
| Last price | $246.1 |
|---|---|
| Day change | +2.30 (0.95%) |
| Market cap | $434.9B |
| P/E (TTM) | 69.52x |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |